ASCO 2021: Updates in Myeloproliferative Neoplasms
This publication covers a multitude of presentations in myeloproliferative neoplasms that were presented and discussed during the 2021 ASCO Annual Meeting.
Volume: 1
Issue: 1
ASCO 2021: Updates in Genitourinary Cancers
This publication provides coverage of data in genitourinary cancers that were presented at the 2021 ASCO Annual Meeting.
My Treatment Approach: Lung Cancer Practice Patterns
The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer
2021 EBMT Annual Meeting
Coverage of the 2021 EBMT Annual Meeting, held virtually March 14-17, 2021.
Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer
Volume: 01
Issue: 01
2021 Genitourinary Cancers Symposium
Volume: 02
2021 Gastrointestinal Cancers Symposium
Updates in NRG1+ Tumors
My Treatment Approach: BRAF+ Melanoma
ASH 2020: CAR T-Cell Therapy Updates
Frontline Immunotherapy Updates in Advanced NSCLC
Year in Review: HER2+ Updates in Oncology
Updates in Relapsed/Refractory AML
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 2
Issue: 2
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
SABCS 2020: Reflections in HER2+ Breast Cancer
Current and Emerging Trends in Chronic Myeloid Leukemia
Updates and Advances in Basal Cell Carcinoma
Volume: 2
My Treatment Approach: Locally Advanced Lung Cancer
Utilizing Tumor Metabolism in Solid Malignancies
Updates in ESR1-Mutant Breast Cancer
My Treatment Approach: Multiple Myeloma
My Treatment Approach: Chronic Lymphocytic Leukemia
Advances in Immunotherapy in Metastatic Non–Small Cell Lung Cancer
Role of Trop-2 as an Actionable Biomarker in Solid Tumors
The Role of Chemotherapy and Novel Combinations in Triple Negative Breast Cancer
ESMO 2020 Congress: Focus in Genitourinary Cancers
Updates and New Targets in NSCLC: An OncLive® Scientific Interchange and Workshop
2020 EBMT Meeting Reporter
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer